Vold Vision is an FDA Clinical Research Facility led by Dr. Michael McFarland. We have made this commitment to our community and our field of opthalmology in order to offer the latest and best technology and care to our patients. We have been credientialed at the highest levels and continually go through regular auditing and review processes to ensure we are conducting clinical trials to the upmost degree. Research is critical in any medical field, and in eye care, there are a multitude of procedures and diseases such as glaucoma, cataracts, and macular degeneration, that do not yet have a cure. The hope is to find a cure for these diseases so that we can treat people earlier or offer better procedures or pharmaceutical therapy.
Our team has conducted numerous clinical trials for glaucoma, cataracts, and refractive type procedures. We have 6 to 12 clinical trials going on at any time. One of the many benefits of having a clinical research facility in Northwest Arkansas is our patients have access to procedures and pharmaceutical therapy they would not have access anywhere else.
Our research team is humbled and honored to have helped usher in groundbreaking procedures like the CyPass Micro-Stent and the XEN Gel Stent. Our patients and doctors involved in these studies, literally helped move glaucoma care forward for future generations.
Patients are evaulated for our research studies in our regular clinic. Our doctors will screen the patients and let them know if they qualify. Patients are typically eager as the benefits of being a study candidate are many, which include receiving new innovative treatment and reduced cost of care. Some patients receive a stipend for particiating in studies. If you are interested in participating, please feel free to call our office and ask to speak with our research coordinators Corinna or Iryna.
Dr. Vold has pioneered Micro-invasive Gluacoma MIGS thanks to the help of the CyPass Micro-Stent, an Implant that is used for glaucoma. The FDA approved the CyPass Micro-Stent, and Vold Vision spent a number of months testing and researching the use and outcomes for patients with both glaucoma and cataracts. The CyPass is a device for treatment for patients who have mild to moderate primary open-angle glaucoma. It has proven to be especially useful for patients who are undergoing cataract surgery at the same time. Vold Vision's research center and our team of outstanding eye surgeons continue to test and validate the exceptional results the Cypass brings our patients. Dr. Vold was the first eye surgeon in the state of Arkansas to perform the CyPass procedure and today we have patients who visit Vold Vision from across the nation to have this revolutionary glaucoma treatment.